Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

Diabetes Care

Volumn 19, Issue 6, 1996, Pages 667-670

  Cincotta, Anthony H ^a   Meier, Albert H ^a  

^a Ergo Science Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE;

ADULT; ARTICLE; BODY FAT; CALORIC RESTRICTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE TOLERANCE; HUMAN; MALE; OBESITY; SKINFOLD THICKNESS; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0029984828     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.6.667     Document Type: Article

References (25)

1. Cincotta AH, Schiller BC, Meier AH: Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 40:639-644, 1991
2. Cincotta AH, MacEachern TA, Meier AH: Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 264:E285-E293, 1993
3. Cincotta AH, Meier AH: Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sci 45:2247-2254, 1989
4. Cincotta AH, Meier AH, Southern LL: Bromocriptine alters hormone rhythms and lipid metabolism in swine. Ann Nutr Metab 33:305-314, 1989
5. Southern LL, CIncotta AH, Meier AH, Binder TD, Watkins KL: Bromocriptine induced reduction of body fat in pigs. J Anim Sci 68:931-936, 1990
6. Meier AH, Cincotta AH, Lovell WC: Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type 11 diabetics. Experientia 48:248-253, 1992
7. Durnin JVGA, Rahaman MM: The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr 21:681-689, 1967
8. American Diabetes Association, Nutritional recommendations and principles for individuals with diabetes mellitus. Diabetes Care 10:126-132, 1987
9. Harris JA, Benedict FG: A biometric study of basal metabolism in man. Washington, DC. The Carnegie Institute, 1919:1-266
10. Gotto AM Jr, Foreyt JP, Goodrick GK: Evaluating commercial weight-loss clinics. Arch Intern Med 142:682-683, 1982
11. Carruba MO, Ricciardi S, Muller EE, Mantegazza P: Anorectic effect of lisuride and other ergot derivatives in the rat. Eur J Pharmacol 64:133-141, 1980
12. Borer KT: Regulation of energy balance in the golden hamster. In The Hamster: Reproduction and Behavior. Siegel HI, Ed. New York, Plenum, 1985, p. 363-408
13. Cincotta AH, Meier AH: Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus). J Endocrinol 106:173-176, 1985
14. Blaxter KL: Methods of measuring the energy metabolism of animals and interpretation of results obtained. Fed Proc 30: 1436-1443, 1971
15. Hartsook EW, Hershberger TV: Interactions of major nutrients in whole animal energy metabolism. Fed Proc 30:1466-1473, 1971
16. Donahoe CP Jr, Lin DH, Kirschenbaum DS, Keesey RE: Metabolic consequences of dieting and exercise in the treatment of obesity. J Consult Clin Psychol 52:827-836, 1984
17. Foster GD, Wadden TA, Feurer ID, Jennings AS: Controlled trial of the metabolic effects of a very-low-calorie diet: short and long term effects. Am J Clin Nutr 51:167-172, 1990
18. Cincotta AH, Meier AH: Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 44:1349-1355, 1995
19. Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico A, Ferrannini E: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 36:502-506, 1987
20. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 72: 96-107, 1991
21. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166, 1995
22. Kissebah AH: Insulin resistance in visceral obesity. Int J Obes 15:109-115, 1991
23. Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 14: 1132-1143, 1991
24. Cincotta AH, Meier AH, Taylor E, Hudson M: Bromocriptine (Ergoset) reduces body fat, hyperinsulinemia and glucose intolerance in obese subjects. Diabetes 44 (Suppl. 1): 168A, 1995
25. Weil C: The safety of bromocriptine in hyperprolactinaemic female fertility: a literature review. Curr Med Res Opinion 10: 172-195, 1986